Vectors, compositions and methods for providing exogenous Nav1.1 activity via CAV-2 mediated delivery of SCN1A expression cassettes
Delivering exogenous Nav1.1 channels through CAV-2 vectors solves the problem of preventing refractory epilepsy and SUDEP in DS treatment, and realizes effective treatment of Dravet syndrome, especially in severe stages to significantly improve survival and improve survival rates and improve Cognitive function.
Patent Information
- Application Number
- CN202380033579.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-11
- Filing Date
- 2023-04-11
- Publication Date
- 2024-11-22
AI Technical Summary
Existing treatments for Dravet syndrome (DS) are difficult to effectively prevent severe refractory epilepsy seizures and sudden death of unknown epilepsy (SUDEP), especially in the severe stage of the disease, and the safety and efficiency of traditional gene therapy vectors such as AAV and HAdV are present. question.
Canine adenovirus type 2 (CAV-2) vector carries the SCN1A expression cassette, and uses coxsackie virus and adenovirus receptor as attachment molecules, preferentially deliver exogenous Nav1.1 channels in neurons, using its reverse axons. Transportation capacity achieves expression across brain regions, enhancing neuronal specificity and long-term transgene expression.
It significantly improved the survival rate of DS mice, reduced spontaneous seizures and epilepsy spike wave frequency, increased the temperature threshold for thermal seizures, improved cognitive function, and provided preventive effects on SUDEP in severe stages.
Smart Images

Figure CN119013409A_ABST
Abstract
Description
Background Art
[0001] Dravet syndrome (DS) is a rare and severe inherited neurological form of developmental epileptic encephalopathy (DEE). Children with DS appear to develop normally during the first six months of life, but then begin to exhibit febrile seizures. During the following months, recurrent refractory spontaneous seizures become increasingly frequent, and global developmental delay sets in. Disease progression includes intellectual disability, behavioral and movement disorders, and a high mortality rate. This is a better known rare disease in which epilepsy is one of the primary symptoms. Early in the school years, during the chronic phase of the disease, the frequency of seizures decreases, but non-epileptic comorbidities persist.
[0002] Previously known as severe myoclonic epilepsy of infancy, DS is caused in most cases by loss-of-function (LoF) mutations in one of the two copies of SCN1A. The vast majority of cases are caused by de novo mutations in one copy of SCN1A that result in LoF and, therefore, haploinsufficiency of the activity of the voltage-gated sodium channel Nav1.1. Due to these mutations, patients with DS fail to produce adequate levels of functional Nav1.1 sodium channels, thereby preventing inhibitory neurons from firing normally. The result is an imbalance between excitation and inhibition in the brain that leads to intractable epilepsy, intellectual disability, and behavioral and movement disorders.
[0003] The first generation of therapies for treating DS focused primarily on addressing symptoms, for example, by improving seizure control using anti-epileptic drugs. This includes compounds directed against traditional epilepsy targets, such as GABA receptors, as well as novel first-in-class therapeutics that target new pathways that have not been used for epilepsy before. In recent years, DS has received great attention from the pharmaceutical industry. Following the approval of Diacomit (stiripentol) from Biocodex and Epidiolex / Epidyolex (oral cannabidiol formulation) from GW Pharmaceuticals, Zogenix's Fintepla (fenfluramine) recently became the third drug approved by the FDA and EMA for the treatment of epileptic seizures in DS.
[0004] Importantly, sodium channel blockers, which are typically the first-line drugs used to treat epilepsy, are contraindicated in DS and may exacerbate the severity of the disease. Most patients must take three or more anti-epileptic drugs in combination, the most common being valproate, clobazam, stiripentol, and topiramate and levetiracetam. None of these drugs alone achieves complete seizure suppression, and only a minority (about 10%) of patients become seizure-free.
[0005] Following in the footsteps of the most advanced cannabidiol formulation Epidiolex and the most advanced serotonergic drug Fintepla, there is an emerging class of second-generation therapeutic agents. Most of these compounds also have the potential to treat other forms of epilepsy.
[0006] As the DS pipeline becomes more mature and competition increases, the focus is shifting toward less symptomatic treatments and more disease-targeted therapies. Third-generation therapies aim to restore abnormal Nav1.1 channel function or expression levels. Several types of disease-targeted gene therapy approaches are currently in development.
[0007] So-called "read-through therapies," such as the types produced by PTC Therapeutics and Tevard Biosciences, enable the ribosome to move past nonsense mutations to complete a functional protein. A nonsense mutation is a mutation that introduces a premature stop codon into a gene sequence, preventing the cell from making a complete protein. Despite the promise, investigator-sponsored studies evaluating the safety and efficacy of ataluren for treating DS caused by nonsense mutations have failed to show efficacy.
[0008] Tevard Biosciences announced that it is developing two novel tRNA-based gene therapy platforms for the treatment of DS and other rare diseases caused by haploinsufficiency and / or nonsense mutations that are not amenable to traditional approaches to gene therapy. Tevard’s approach focuses on mRNA stabilization and nonsense codon suppression (or read-through).
[0009] Stoke Therapeutics is developing the first disease-modifying treatment for DS, an antisense oligonucleotide (ASO) therapy targeting SCN1A pre-mRNA maturation, which upregulates Nav1.1 protein expression in rodents, human cell lines, and non-human primates. The lead candidate uses Stoke's TANGO (Targeted Increase of Nuclear Gene Output) technology to target RNA splicing and increase protein expression in diseases caused by haploinsufficiency. The program, named STK-001, follows a similar approach to Spinraza and will be administered via intrathecal injection into the spinal fluid.
[0010] In mice with Scn1a haploinsufficiency, a single intracerebroventricular dose of the lead ASO increased Nav1.1 production and met two primary preclinical endpoints in a DS mouse model, seizure reduction and animal survival. Stoke also showed biodistribution and target engagement of STK-001 in non-human primates (AES2019 meeting) and dosed the first patient in a Phase 1a / 2b study in August 2020.
[0011] Encoded Therapeutics is developing an adeno-associated virus (AAV)-based gene therapy to increase SCN1A transcription and rescue haploinsufficiency in patients with DS. The treatment, named ETX101, has the potential to become the second disease-modifying treatment to enter clinical trials for the treatment of DS, following Stoke Therapeutics' ASO lead program. ETX101 was granted Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA for the treatment of SCN1A+ DS.
[0012] SCN1AORF lacks amenability to AAV-based gene therapy due to limited cloning capacity of <5,000nt. Encoded Therapeutics attempted to overcome the limitations of AAV viral gene therapy by expressing engineered transcription factors to upregulate Senia expression in these cells, and presented preclinical data for their program in 2019, showing GABAergic cell-specific expression of SCN1A mRNA and Nav1.1 channels in a mouse model of DS, resulting in reduced seizures and mortality. In December 2020, the company also presented data on the biodistribution of ETX101 in non-human primates.
[0013] The present disclosure relates to methods for providing exogenous Nav1.1 via delivery of an SCN1A expression cassette vector into the central nervous system (CNS). This strategy is suitable as a therapeutic approach regardless of the underlying SCN1A mutation. In addition, since the treatment compensates for the LoF of Nav1.1, it can potentially improve DS epilepsy and non-epileptic comorbidities as well as Alzheimer's disease and other Nav1.1-related pathological conditions. The minimum size of the expression cassette is approximately 7 kbp. To overcome the "size" barrier, previous gene therapy strategies for DS include (i) enhancing the expression of endogenous Senia via transcriptional activation (Colasante et al., 2019; Han et al., 2020; Yamagata et al., 2020); (ii) overexpression of Scn1b auxiliary subunits for increasing the efficacy of the channel complex; and (iii) antisense oligonucleotide-mediated SCN8A downregulation.
[0014] While previous approaches to treat DS have shown potential improvement in "DS mice," the therapeutic potential in these approaches has only been shown in cases of mild DS when administered shortly after birth during the asymptomatic, pre-epileptic stage. In essence, these approaches do not distinguish between models with severe symptoms and mild symptoms. Clinical efficacy in severe cases of DS pathology has not been established. Furthermore, because clinical diagnosis is rarely confirmed before progression to recurrent spontaneous seizures, treatments to prevent the onset of severe intractable seizures and unexplained sudden death in epilepsy (SUDEP) are urgently needed.
[0015] Clinical trials for DS shifted in 2020 with the initiation of the first clinical trial by Stoke Therapeutics of a treatment specifically designed to increase Nav1.1 activity, STK-001. There are additional genetic and potentially disease-modifying treatments in early and late preclinical development, including AAV-based gene therapies.
[0016] Compared with AAV, adenovirus (AdV) vectors can carry up to 36kbp of exogenous sequences. Similar to AAV vectors, some AdV types (e.g., E1-deficient and auxiliary-dependent CAV-2 vectors) can produce long-term transgenic expression in rodent and primate brains. In addition, human AdV (HAdV) carrying the SCN1A expression cassette injected into the CNS of adolescent DS mice is well tolerated and reduces epilepsy in the chronic phase. Although AAV vectors have shown some promise in clinical trials, there are still safety issues, including the extremely high doses required and the tendency of AAV vectors to integrate into the genome of transduced cells. Like HAdV-based vectors, most AAV vectors are also easily absorbed by non-neuronal cells (including those cells that present antigens to immune cells). In addition, most potential patients will have cross-reactive memory T cells that recognize conservative AAV epitopes. Therefore, the use of AAV and HAdV as neuronal gene therapy vectors may pose risks. Additionally, recent evidence suggests that AAV vectors are not as safe as initially thought, with liver toxicity, hematologic toxicity, neurological safety issues, and cancer issues reported following AAV-mediated gene therapy, leading to the early termination of two studies (Mullard, 2021).
[0017] Therefore, there is a need for gene transfer vectors that allow for preferential uptake into neurons via vectors capable of carrying large expression cassettes for delivery of SCN1A to the brain. Summary of the invention
[0018] The vast majority of DS cases are caused by de novo mutations in one copy of SCN1A that result in LoF and, therefore, haploinsufficiency of the activity of the voltage-gated sodium channel Nav1.1. Therefore, a strategy in which exogenous Nav1.1 channels are provided into CNS neurons could be used as a suitable treatment regardless of the underlying SCN1A mutation. Furthermore, since this treatment compensates for the LoF of Nav1.1, it could potentially improve epileptic and non-epileptic comorbidities as well as Alzheimer's disease and other Nav1.1-associated pathological conditions.
[0019] One treatment method is gene therapy, in which exogenous Nav1.1 is provided via delivery of an SCN1A expression cassette. The gene therapy pipeline is closely related to vector efficacy. Due to the lack of vectors capable of carrying large expression cassettes, several rare diseases have little hope of becoming targets for gene replacement. Due to the complex pathophysiology of Nav1.1-related pathological conditions (such as DS and Alzheimer's disease), etiological methods (such as gene therapy) have a unique opportunity to obtain a comprehensive improvement in the lives of these patients. However, several challenges to treatment include large (6kb) SCN1AORF, which excludes the effective expression of some viral vectors, supraphysiological Nav1.1 levels in non-neuronal cells may be harmful, sufficient neurons in infection-related areas and the possibility of providing long-term expression. The present disclosure relates to a gene transfer vector and a treatment method that will pave the way for clinical trials of DS, epilepsy, Alzheimer's disease and other genetic diseases and pathological conditions associated with miscoded Nav1.1.
[0020] Due to the approximately 6kbp ORF of the commonly used vector SCN1A, adeno-associated viruses (AAV) are not very suitable. Compared with AAV, AdV vectors can carry up to 36kbp of exogenous sequences (Cots et al., 2013; del Rio et al., 2019; Parks et al., 1996). AdV-mediated transgenic expression is also stable in the brains of rodents for at least 1 year (Soudais et al., 2004). In addition, human AdV carrying SCN1A injected into the CNS of adolescent mice with DS was well tolerated and reduced epilepsy in the chronic phase (Mora-Jimenez et al., 2021). However, HAdV lacks neuronal specificity, relies on a different non-neuronal specific promoter CAG, and only shows efficacy in improving epilepsy and behavioral problems in older mice with less severe DS expression.
[0021] DS mice have a mortality rate of approximately 50%-60%, with most deaths concentrated in the 4th week of life. DS mice that survive beyond P28 are less likely to die, and they have a reduced frequency of seizures. Previously, studies have been conducted on mice aged approximately 5 weeks in which their brains were injected with HAdV carrying an SCN1A expression cassette. However, by treating adolescent mice at five weeks of age, these studies pre-selected mice with milder DS pathology, since the severe stage of DS corresponds to the 4th week of life. These studies were not associated with reversal of DS at a severe stage of the disease when epilepsy is most severe and premature mortality occurs at a high rate.
[0022] The present disclosure relates to canine adenovirus type 2 (CAV-2)-mediated delivery of SCN1A ORF for use in the treatment of SCN1A mutations and Nav1.1 sodium channel miscoding and rescue of severe stages of DS and prevention of premature death. For example, in certain embodiments, the present disclosure relates to CAV-2-mediated delivery of SCN1A ORF expression cassettes for use in the treatment of SCN1A mutations and Nav1.1 sodium channel miscoding. This can rescue severe DS and prevent premature death. It will also provide significant therapeutic value in the treatment of Alzheimer's disease and other Nav1.1-related pathological conditions.
[0023] CAV-2 vectors provide significant advantages for gene transfer to CNS. First, by preferentially using coxsackievirus and adenovirus receptors (CAR) as attachment molecules (whose expression is mainly found by neurons in the brain parenchyma), CAV-2-mediated gene transfer is limited to neurons. Secondly, the cloning capacity of 35kbp provides the ability to include different promoter sequences, making it possible to control expression in various sub-neuronal populations. Finally, due to its strong ability to reverse axonal transport, CAV-2 vector injection can lead to expression across connected brain regions.
[0024] In some aspects, the disclosure relates to a CAV-2 vector comprising a region of SCN1AORF. The disclosure also relates to an engineered CAV-2 vector comprising a region of SCN1AORF and further comprising an inducible promoter region for controlling the expression of SCN1AORF. The disclosure also relates to a CAV-2 vector. In certain embodiments, the CAV-2 vector can be enhanced for selective neuronal transgenic expression. The disclosure also relates to a CAV-2 vector comprising a region of SCN1A ORF, and may also comprise a region encoding controlled (e.g., transcription or translation, or post-translation) SCN1A transcription, mRNA processing, protein stability, or protein targeting.
[0025] In some aspects, the present disclosure relates to CAV-2-mediated CNS delivery of SCN1A ORF (CAV-2SCN1A treatment) for rescuing DS and preventing premature death. For example, the present disclosure relates to CAV-2SCN1A treatment for rescuing DS and preventing premature death in mice with DS during severe stages of the disease, and for correcting DS comorbidities. Importantly, exogenous Nav1.1 activity in adolescent mice that survived to the chronic stage of DS and in young mice with severe epileptic seizures treated with CAV-2SCN1A increased the survival rate of mice, reduced the occurrence of spontaneous epileptic seizures and epileptic spike frequency, and increased the temperature threshold for febrile epileptic seizures. The present disclosure relates to the effective delivery of SCN1A expression cassettes in excitatory and inhibitory neurons as a feasible treatment method for rescuing and treating DS. The present disclosure also relates to the treatment of DS, and specifically, treatment with CAV-2-mediated CNS delivery of SCN1A ORF in animal models with DS to correct DS comorbidities.
[0026] In some aspects, the present disclosure relates to the design and use of CAV-2 vectors for transferring SCN1A ORF to the CNS to treat DS. By preferentially using coxsackievirus and adenovirus receptors (CARs) as attachment molecules (whose expression is primarily found by neurons in the brain parenchyma), CAV-2-mediated gene transfer is limited to neurons. The cloning ability of CAV-2 provides the ability to include different promoter sequences, enabling control of expression in various sub-neuronal populations. Additional features include its retrograde axonal transport ability, allowing CAV-2-mediated transduction to result in expression across multiple connected brain regions.
[0027] In another aspect, the present disclosure relates to a suitable promoter included in an expression cassette for the SCN1A ORF, which is incorporated into the sequence of a CAV-2 vector. The promoter can be used for the purpose of controlling the expression level of the SCN1A ORF. The promoter can also be selected based on the need to modify the neuronal tropism of the vector. The CAV-2 sequence can also be engineered for the purpose of selective neurons and stable long-term expression.
[0028] In another aspect, the disclosure relates to a method for producing an engineered CAV-2SCN1A therapeutic vector. Production is carried out according to a method developed by a collaborating center (CNRS, Montpellier), which relies on the use of a helper CAV-2 vector. The helper vector replicates with the CAV-2SCN1A therapeutic vector, but the infectious helper vector particles are not encapsidated because their packaging sequences (flanked with lox sequences) are eliminated by the Cre recombinase.
[0029] In other embodiments, the present disclosure relates to the effective delivery of SCN1A expression cassettes in excitatory and / or inhibitory neurons as a viable treatment for DS. Thus, the present disclosure relates to a strategy in which exogenous functional Nav1.1 channels are provided to CNS neurons via CAV-2-mediated delivery of the SCN1A ORF as a treatment approach suitable for children and adolescents, regardless of the underlying SCN1A mutation. In addition, the present disclosure relates to a treatment that compensates for the LoF of Nav1.1, and can improve DS epilepsy and non-epileptic comorbidities, and achieve rescue and reversal of DS, as well as provide treatments and therapeutic methods for Nav1.1-related pathological conditions.
[0030] Thus, based on the foregoing and continuing description, the present invention, in its various embodiments, may include one or more of the following features in any non-mutually exclusive combination:
[0031] A vector for providing an exogenous Nav1.1 sodium channel, which has a first nucleic acid sequence encoding at least a portion of a CAV-2 genome;
[0032] A vector for providing exogenous Nav1.1 sodium channel, which has a second nucleic acid sequence encoding a functional Nav1.1 sodium channel;
[0033] A vector for providing exogenous Nav1.1 sodium channel, which has a first regulatory sequence encoding a transcription control region,
[0034] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding at least one promoter / enhancer / elongation factor.
[0035] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding E2, E6, EF1, CAG, hSyn, D1x5 / 6 and NSE, and preferably NSE;
[0036] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding an endogenous SCN1A promoter;
[0037] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding an endogenous SCN1A enhancer;
[0038] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding an endogenous SCN1A transcription factor;
[0039] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding an endogenous SCN1A promoter;
[0040] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding an endogenous SCN1A enhancer;
[0041] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding E6;
[0042] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding EF1;
[0043] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding CAG;
[0044] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding hSyn;
[0045] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding Dlx5 / 6;
[0046] A vector for providing exogenous Nav1.1 sodium channel, wherein the transcription control region contains a promoter / enhancer / elongation factor sequence encoding NSE;
[0047] A vector for providing exogenous Nav1.1 sodium channel, wherein a second nucleic acid sequence is operably linked to a first regulatory sequence for controlling transcriptional expression of an SCN1A open reading frame (ORF) in mammalian cells;
[0048] A vector for providing exogenous Nav1.1 sodium channel, wherein the second nucleic acid sequence is sequence ID No. 12;
[0049] A vector for providing exogenous Nav1.1 sodium channel, wherein the second nucleic acid sequence is sequence ID No. 14;
[0050] A vector for providing exogenous Nav1.1 sodium channel, wherein the second nucleic acid sequence encodes Sequence ID No. 15;
[0051] A vector for providing exogenous Nav1.1 sodium channel, wherein the second nucleic acid sequence encodes Sequence ID No. 16;
[0052] A vector for providing exogenous Nav1.1 sodium channel, wherein the second nucleic acid sequence is an engineered SCN1A ORF;
[0053] A vector for providing exogenous Nav1.1 sodium channel, wherein the engineered SCN1A ORF is generated by eliminating at least one short repeat sequence from the codon-modified SCN1A ORF;
[0054] A vector for providing an exogenous Nav1.1 sodium channel, wherein the second nucleic acid sequence is generated by eliminating at least one short repeat sequence in the ORF encoding the transmembrane portion of the functional Nav1.1 sodium channel;
[0055] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector is designed for use in the treatment of a pathological condition associated with an SCN1A mutation;
[0056] A vector for providing exogenous Nav1.1 sodium channel, which has an NSE promoter;
[0057] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector is therapeutically active in an individual having a SCN1A missense mutation or a SCN1A truncating mutation;
[0058] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector is optimized for preferential expression of the SCN1A ORF in neurons;
[0059] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector is therapeutically active in an individual suffering from Dravet syndrome;
[0060] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector has therapeutic activity in an individual suffering from epilepsy;
[0061] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector has therapeutic activity in an individual suffering from Alzheimer's disease;
[0062] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector is therapeutically active in an individual with autism spectrum disorder;
[0063] A vector for providing exogenous Nav1.1 sodium channels, wherein the vector has therapeutic activity in an individual suffering from a neuronal dysfunction;
[0064] A vector for providing exogenous Nav1.1 sodium channels, wherein the vector is therapeutically active in an individual suffering from a network dysfunction;
[0065] A vector for providing exogenous Nav1.1 sodium channel, wherein the vector is therapeutically active in an individual with endogenous Nav1.1 functional deficiency;
[0066] A method for providing exogenous Nav1.1 channels via a vector, the method comprising administering a therapeutically effective amount of any of the aforementioned vectors, including a vector for providing exogenous Nav1.1 sodium channels;
[0067] A method for providing exogenous Nav1.1 channels via a vector, comprising administering the vector into the central nervous system of a mammal;
[0068] A method for providing exogenous Nav1.1 channels via a vector, comprising administering the vector to at least one brain region;
[0069] A method for providing exogenous Nav1.1 channels via a vector, comprising administering the vector into the hippocampus;
[0070] A method for providing exogenous Nav1.1 channels via a vector, comprising administering the vector into the thalamus;
[0071] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered prior to the development of a chronic form of Dravet syndrome or a comorbidity thereof;
[0072] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to treat a chronic form of Dravet syndrome or a comorbidity thereof;
[0073] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to treat Dravet syndrome or a comorbidity thereof;
[0074] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to prevent the development of Dravet syndrome or a comorbidity thereof;
[0075] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a missense mutation in SCN1A;
[0076] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a nonsense mutation in SCN1A;
[0077] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a truncating mutation in SCN1A;
[0078] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a deletion mutation in SCN1A;
[0079] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a frameshift mutation in SCN1A;
[0080] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a splice site mutation in SCN1A;
[0081] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a mutation in SCN1A;
[0082] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a mutation in the promoter / enhancer / regulatory region of SCN1A;
[0083] A method for providing exogenous Nav1.1 channels via a vector, wherein after administering the vector, the method further comprises inducing expression of a functional Nav1.1 sodium channel;
[0084] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered to an individual having a missense mutation in SCN1A or a truncating mutation in SCN1A;
[0085] A method for providing exogenous Nav1.1 channels via a vector, wherein after administering the vector, the method further comprises monitoring the mammal for a desired clinical outcome, and administering a second therapeutically effective amount of the vector if the desired clinical outcome is not achieved;
[0086] A method for providing exogenous Nav1.1 channels via a vector, wherein the vector is administered into the brain of a patient via injection;
[0087] A method for providing exogenous Nav1.1 channels via a vector, the method comprising administering a therapeutically effective amount of a seizure drug;
[0088] A method for providing exogenous Nav1.1 channels via a carrier, the method comprising administering a therapeutically effective amount of an Alzheimer's disease drug;
[0089] A method for providing exogenous Nav1.1 channels via a vector, the method comprising administering a therapeutically effective amount of an epilepsy drug;
[0090] A method for providing exogenous Nav1.1 channels via a vector, wherein a therapeutically effective amount of the vector is administered to treat Dravet syndrome;
[0091] A method for providing exogenous Nav1.1 channels via a vector, wherein a therapeutically effective amount of the vector is administered to treat epilepsy;
[0092] A method for providing exogenous Nav1.1 channels via a vector, wherein a therapeutically effective amount of the vector is administered to treat Alzheimer's disease;
[0093] A method for providing exogenous Nav1.1 channels via a vector to modify brain neural networks to alleviate symptoms of pathological conditions.
[0094] A method for providing exogenous Nav1.1 channels via a vector to modify brain neural networks to alleviate symptoms of autism spectrum disorder (ASD).
[0095] A composition for providing exogenous Nav1.1 channel, the composition comprising any one of the aforementioned vectors, or a vector for providing exogenous Nav1.1 sodium channel. BRIEF DESCRIPTION OF THE DRAWINGS
[0096] Figure 1 .Promoter-driven variation in transgene expression from CAV-2 vectors.
[0097] Figure 1.1 . Enhancer / promoter driven variation in transgene expression from CAV-2 vectors.
[0098] Figure 2 .Functional expression of SCN1A ORF.
[0099] Figure 3 . Survival of adolescent mice after injection of CAV-GFP or CAV-SCN1A.
[0100] Figure 4 Hippocampal injection of CAV-SCN1A improves epilepsy and cognitive abilities in the chronic stage of DS.
[0101] Figure 5 . Sexually divergent effects after CAV-SCN1A injection into the hippocampus.
[0102] Figure 6 .Behavioral characterization of male and female mice.
[0103] Figure 7Hippocampal injection of CAV-SCN1A improves the epileptic phenotype in severe stages of DS.
[0104] Figure 8 .Video monitoring of convulsive spontaneous epileptic seizures.
[0105] Fig. 9 Correction of background ECoG activity and partial correction of cognitive function after treatment with CAV-SCN1A.
[0106] Fig.10 .Relative expression of voltage-gated sodium channels.
[0107] Fig.11 .Thalamic injection of CAV-SCN1A ameliorates the DS phenotype in young mice.
[0108] Fig.12 Similar effects of CAV-SCN1A injection into the thalamus of male and female DS mice.
[0109] Fig.13 .Combined thalamic and hippocampal injections of CAV-SCN1A protect against heat-induced seizures in young mice.
[0110] Fig.14 Similar effects of CAV-SCN1A injections into the thalamus and hippocampus of male and female DS mice.
[0111] Fig.15 Effects of CAV-SCN1A injection into the hippocampus and / or thalamus of young mice.
[0112] Fig.16 .(A) Maps of two CAV-2 vectors carrying either the mCitrine cassette or the codon-modified SCN1A cDNA with a fused HA tag, and the experimental design of the study in which they were bilaterally injected into the hippocampus of a mouse model of Alzheimer's disease. ITR: inverted terminal repeat. ψ: packaging signal. NSE (promoter): neuron-specific enolase. pA: polyadenylation signal. (B) Expression patterns of vectors injected into the hippocampus. The second and third columns are higher magnifications of the black and white boxes of the first column, respectively. (C) Therapeutic effects of CAV-NSE-SCN1 A-HA on working memory in the Y-maze test of 4- and 5-month-old J20 and 5XFAD mice. (DE) Analysis and quantification of amyloid burden (white boxes) in the hippocampus and cortex of 9-month-old J20 mice. DETAILED DESCRIPTION
[0113] The following and this article provide a detailed description of one or more embodiments of the claimed subject matter and drawings illustrating the principles of the claimed subject matter. The claimed subject matter is described in conjunction with such embodiments, but is not limited to any particular embodiment. It should be understood that the claimed subject matter can be embodied in various forms and covers many alternative forms, modified forms and equivalents. Therefore, the specific details disclosed herein should not be interpreted as limiting, but as the basis of the claims and as a representative basis for teaching those skilled in the art to adopt the claimed subject matter in virtually any appropriately detailed system, structure or manner. In order to provide a thorough understanding of the present disclosure, many specific details are set forth in the following specific embodiments. These details are provided for the purpose of example, and the claimed subject matter can be practiced according to the claims without some or all of these specific details. It should be understood that other embodiments can be used and structural changes can be made without departing from the scope of the claimed subject matter. It should be understood that the various features and functions described in one or more separate embodiments are not limited to the specific embodiments in which they are described in terms of their applicability. On the contrary, they can be applied to one or more other embodiments of the present disclosure alone or in some combination, whether or not such embodiments are described, and whether or not such features are presented as part of the described embodiments. For the purpose of clarity, technical material that is known in the technical fields related to the claimed subject matter has not been described in detail so that the claimed subject matter is not unnecessarily obscured.
[0114] All headings are for the convenience of the reader and, unless so specified, should not be used to limit the meaning of the text that follows the heading.
[0115] Throughout this disclosure, various aspects of the claimed subject matter are presented in a range format. It should be understood that the specific implementation of the range format is only for convenience and simplicity, and should not be interpreted as an unchangeable limitation on the scope of the claimed subject matter. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and each numerical value in the range. For example, in the case of providing a range of values, it should be understood that each intermediate value between the upper and lower limits of the range and any other specified value or intermediate value in the specified range are included in the claimed subject matter. The upper and lower limits of these smaller ranges can be independently included in the smaller range, and are also included in the claimed subject matter, subject to any special exclusion restrictions in the specified range. In the case where the specified range includes one or both of the limits, the scope excluding any one or both of the included limits is also included in the claimed subject matter. Regardless of the width of the range, this applies. For example, a description of a percentage range such as at least 75 should be considered to have specifically disclosed sub-ranges such as 75 to 100, 80 to 100, 85 to 100, 95 to 100, 99 to 100, etc., as well as individual numbers within that range, e.g., 75, 76, 77, 78, 79, etc.
[0116] Transcriptionally targeted transgene expression
[0117] Currently, DS is believed to be caused by dysfunction of inhibitory neurons. It is also postulated that reduced Nav1.1 activity in excitatory neurons may also be associated with DS comorbidity. In addition, hippocampal dysfunction may play a key role in DS pathophysiology.
[0118] Enhancer / promoter driven variation in CAV-2 vector expression
[0119] The assay was started to determine whether selective targeted expression could be achieved in different neuronal populations in the hippocampus and afferent areas. Because selective targeting of infection of various neuronal subtypes is not technically feasible, the transcriptional control of the expression cassette was selected to achieve targeted neuronal expression. For this purpose, a CAV-2 vector containing fluorescent reporters driven by the following items: i) a strong non-specific CAG promoter (cytomegalovirus enhancer, chicken b-actin promoter, and rabbit b-globin splice acceptor site), which drives expression in all vector-transduced cells; ii) a human synapsin promoter (hSyn), which drives transgenic expression in most neuronal populations; iii) a neuron-specific enolase (NSE) promoter, which drives moderate levels of transgenic expression in excitatory and inhibitory neurons; iv) a Dlx5 / 6 promoter (Dlx5 and Dlx6 encode two homeobox transcription factors expressed by developmental and mature GABAergic interneurons), which, when incorporated into a viral vector, can lead to preferential expression in inhibitory neurons; Scn1a enhancers E2 and E6.
[0120] After bilateral vector injections into the hippocampus of adolescent mice (5-6 weeks old), expression patterns varied depending on the promoter. As expected, the CAG promoter produced robust and widespread transgene expression at the injection site and, due to retrograde transport of CAV-2, also in excitatory neurons from the subiculum and multiple neocortical layers projecting into the hippocampus ( Figure 1 A to Figure 1 The hSyn promoter also resulted in widespread transgene expression at the injection site and afferent areas, albeit at lower levels ( Figure 1 E to Figure 1 The NSE promoter produces moderate expression levels in excitatory and inhibitory neurons surrounding the injection site (ratio 80%-90% excitatory and 10%-20% inhibitory) as well as additional hippocampal projection areas in the cortex and thalamus ( Figure 1 I to Figure 1 In contrast, using the Dlx5 / 6 promoter, localized transgene expression was observed primarily in hippocampal interneurons ( Figure 1 M to Figure 1 Based on the expression pattern in excitatory and inhibitory neurons, biodistribution, and the possible requirement for moderate levels of Nav1.1, pan-neuronal expression mediated by the NSE promoter was chosen to drive SCN1A expression using the CAV-2 vector.
[0121] Figure 1 Shown are promoter-driven variations in the expression pattern and biodistribution of CAV-2 vectors containing fluorescent reporters in excitatory and inhibitory neurons following bilateral vector injections into the hippocampus of 5- to 6-week-old adolescent mice. Figure 1 A to Figure 1 Panel D shows a CAG promoter driven variation. Figure 1 E to Figure 1 Panel H shows the hSynap promoter driven mutation. Figure 1 I to Figure 1 L in the figure shows the variation driven by the NSE promoter. Figure 1 M to Figure 1 P in Figure 2 shows the variation driven by the Dlx5 / 6 promoter.
[0122] Figure 1.1 The following enhancer / promoter driven variations are shown: column 1 shows the E6 enhancer from SCN1A; column 2 shows the E2 enhancer from SCN1A; column 3 shows Dlx5 / 6; column 4 shows NSE; and column 5 shows CAG.
[0123] Cav-SCN1A-mediated Nav1.1 activity
[0124] In addition to its size, the native SCN1A ORF is prone to rearrangement when subcloned into a plasmid and propagated in Escherichia coli (E. coli). However, codon modification can enhance its stability and therefore facilitate vector production. To further increase the stability of the ORF, short (10bp-15bp) repeat sequences were eliminated from the engineered SCN1A. Most of the short repeat sequences are located in the sequence encoding the transmembrane portion of Nav1.1.
[0125] Detection of exogenous Nav1.1 immunoreactivity can be problematic in the brain where endogenous levels are present. Therefore, to track CAV-SCN1A-mediated Nav1.1 expression, a C-terminal hemagglutinin (HA) tag was also added. CAV-SCN1A was generated and purified as described previously. To determine whether functional Nav1.1 channels were generated, CAV-SCN1A was incubated with DK cells. Robust voltage-gated sodium currents ( Figure 2 A in Figure 2 Notably, the HA tag had no significant effect on the biophysical properties of the channel ( Figure 2 C in Figure 2 D). When injected into the hippocampus of adolescent mice, HA immunoreactivity was readily detected along the dendrites and somata of excitatory neurons and along the dendrites, somata, and axon initial segments of inhibitory neurons in the hippocampus.
[0126] Functional expression of the SCN1A transgene
[0127] Figure 2 Functional expression of the SCN1A transgene was demonstrated. Figure 2 A to Figure 2 B, shows the voltage-current relationship (A) and biophysical properties (B) of sodium current after expression of CAV-SCN1A in DK cells. The half-potential of activation is -30.4±0.74 mV; the half-potential of inactivation is -65.73±0.94 mV. Figure 2 C to Figure 2 D shows the voltage-current relationship and biophysical properties of sodium current in DK cells after expression of CAV-HA-SCN1A in DK cells. The half-potential of activation was -30.6±1.2 mV and the half-potential of inactivation was -67.8±1.8 mV. Figure 2 A and Figure 2Inset in C: Representative sodium current trace, calibrator: 500 pA, 2 ms. Open symbols represent currents recorded from DK cells infected with control CAV-GFP control vector (n=10), and solid symbols represent CAV-SCN1A (n=9) or CAV-HA-SCN1A (n=7), as indicated.
[0128] like Figure 2 E to Figure 2 In U, CAV-HA-SCN1A was used. 1×10 9 Physical pellets were injected bilaterally into the hippocampus of adult mice. Figure 2 E to Figure 2 In N, the background stain is cresyl violet. HA expression is shown by immunohistological DAB staining (dark brown). Approximately 1,000 HA-immunoreactive cells / mouse with neuronal morphology can be easily identified. Figure 2 E and Figure 2 H in Figure 5 shows HA immunoreactivity in the hippocampus. Scale bar 500 μm. Figure 2 F and Figure 2 The I in the figure shows Figure 2 E and Figure 2 The black box in H is enlarged, and Figure 2 K and Figure 2 Additional examples of M. Scale bar 50 μm. Figure 2 G in Figure 2 J in Figure 2 L and Figure 2 N shows magnification of red box. Scale bar 20 μm. OU shows immunofluorescence in mice injected with CAV-HA-SCN1A. Figure 2 O in the figure shows HA immunoreactivity (IR). Figure 2 P in the figure shows GABA IR. Figure 2 The Q in Figure 2 shows the DAPI IR and merged ( Figure 2 R to Figure 2 U in the figure). Scale bar 20 μm.
[0129] CAV-SCN1A injection reverses epileptic phenotype in adolescent DS mice
[0130] There are multiple mouse models of DS that faithfully reproduce the features of DS pathology. These "DS mice" exhibit an age-dependent progression of epilepsy severity, with spontaneous seizures beginning at approximately postnatal (P) day 18, and premature mortality peaking in the 4th week of life. DS mice that survive this severe stage enter a chronic phase in which the frequency of spontaneous convulsive seizures and mortality decrease. Notably, the genetic background significantly affects the severity of the epilepsy phenotype of DS mice.
[0131] Here, we used one of the most demanding DS models, a gene carrying a missense mutation ( SCN1A ) on a C57BL / 6J background. A1783V / WT ). In this model, all mice experienced spontaneous seizures, with an overall mortality rate of over 50%. The mutation was shown to cause LoF of Nav1.1, recapitulating the characteristic neuronal changes of DS. However, unlike other models with SCN1A truncating mutations, the A1783V missense mutation did not affect overall SCN1A mRNA or total Nav1.1 levels.
[0132] Due to retrograde transport of CAV-2 vectors, it is hypothesized that bilateral injection into the hippocampus will be sufficient to ameliorate SCN1A in adolescence A1783V / WT To this end, in healthy (WT) and SCN1A A1783V / WT Pubertal mice (5 weeks old) were bilaterally injected with CAV-SCN1A or CAV-GFP. As mentioned above, the prevalence of sudden unexplained death in epilepsy (SUDEP) is low after P30, during the chronic phase of the disease, such as in 5-week-old adolescent mice (Fadila et al., 2020; Ogiwara et al., 2013; Ricobaraza et al., 2019; Yu et al., 2006). Therefore, in this mock-CAV-GFP injected and treated mouse cohort, only one mock-treated SCN1A A1783V / WT The mouse died.
[0133] like Figure 3 As shown, no mortality occurred in WT mice injected with CAV-GFP or CAV-SCN1A or in DS mice injected with CAV-SCN1A. Premature mortality in DS mice occurred mainly during the 4th week of life. Figure 3 As shown, CAV-SCN1A was tested for its ability to improve the epilepsy phenotype in a subset of mice that survived to the fifth week. Only one DS mouse died prematurely (treated with CAV-GFP). WT: CAV-GFP n=11; WT: CAV-SCN1A n=12; DS: CAV-GFP n=9; DS: CAV-SCN1A n=12.
[0134] With minimal potential for impact on survival, electrocorticography was used to characterize the effects of CAV-SCN1A on abnormal neuronal activity. Two weeks after injection, deep electrodes were implanted in the hippocampus and intracranial electrodes were implanted in the somatosensory cortex for electrocorticographic (ECoG) recordings. Initially, these recordings showed that CAV-SCN1A injections in WT mice did not induce abnormal neuronal activity ( Figure 4 A in Figure 4 In addition, in SCN1A A1783V / WTBilateral hippocampal CAV-SCN1A injections in mice reduced but did not completely eliminate the occurrence of epileptic spikes ( Figure 4 A to Figure 4 D).
[0135] Another characteristic of DS is sensitivity to heat-induced seizures. Effective anti-seizure drugs used to treat humans with DS can raise the threshold for heat-induced seizures in DS mice. Strikingly, about 40% of the CAV-SCN1A-treated DS cohort showed complete protection from seizures up to 40.5°C ( Figure 4 In addition, CAV-SCN1A injections in DS mice that exhibited epileptic seizures also showed reduced susceptibility and increased temperature thresholds ( Figure 4 E). The present disclosure demonstrates that CAV-SCN1A treatment improves SCN1A during the chronic phase of DS. A1783V / WT Efficacy of clinical status and outcomes of epilepsy phenotypes in mice.
[0136] CAV-SCN1A does not alter behavior in WT mice
[0137] Next, the effects of CAV-SCN1A injections in adolescent WT and DS mice were examined using the Y-maze spontaneous alternation test (which assesses working memory based on the mouse's natural curiosity and tendency to explore a novel environment) and the open field test (which monitors activity in a novel environment). No significant differences between the groups were detected ( Figure 4 F). However, if the level of change is random, it was found that WT mice injected with CAV-GFP or CAV-SCN1A showed changes above the random level. A1783V / WT Mice exhibited random exploration of the maze ( Figure 4 F), consistent with their deficits in working memory. Notably, DS mice injected with CAV-SCN1A showed nonrandom exploration that was borderline statistically significant ( Figure 4 F), suggesting some improvement in cognitive ability. CAV-SCN1A had no adverse effect on the performance of WT mice in the open field test ( Figure 4 F).
[0138] The present disclosure demonstrates that CAV-SCN1A has no adverse effects in WT mice, suggesting that overexpression of Nav1.1 is well tolerated and has strong therapeutic potential for both epileptic and non-epileptic DS phenotypes when administered during the chronic phase.
[0139] Hippocampal injection of CAV-SCN1A improves epileptic symptoms and cognitive abilities in the chronic stage of DS .
[0140] Figure 4It also showed that hippocampal injection of CAV-SCN1A in the chronic stage of DS improved epileptic symptoms and cognitive abilities. Figure 4 WT and DS mice at 5 weeks of age were injected with CAV-GFP or CAV-SCN1A as indicated. Figure 4 A to Figure 4 B shows data from two weeks after treatment, when depth electrodes were implanted in the hippocampus at the injection site. Figure 4 The quantification of the spike frequency is shown in A and Figure 4 Shown in B. No epileptic activity was detected in WT mice injected with CAV-GFP or CAV-SCN1A (n=3 each); DS: CAV-GFP (n=6); DS: CAV-SCN1A (n=5). Figure 4 C to Figure 4 D shows an exemplary trace of cortical ECoG recording (C) and quantification of spike frequency (D). WT: CAV-SCN1A (n=2); DS: CAV-GFP (n=6); DS: CAV-SCN1A (n=5). Figure 4 Figure E shows the percentage of mice that remained free of heat-induced seizures. The dashed line indicates the median seizure onset temperature. DS: CAV-GFP, n=13; DS: CAV-SCN1A, n=10. Separate analysis of males and females is shown in Figure 5 . Figure 4 F-Left: Spontaneous alternation in the Y-maze is shown. The dashed line indicates the random level expected for random alternation. The markers above the bars indicate statistical analysis using a one-sample t-test relative to 50%. WT: CAV-GFP (n=9); WT: CAV-SCN1A (n=13); DS: CAV-GFP (n=11); DS: CAV-SCN1A (n=10). Figure 4 F-right in Figure 1: Distance traveled in the open field is shown. Statistical analysis was performed using one-way ANOVA. WT: CAV-GFP (n=14); WT: CAV-SCN1A (n=13); DS: CAV-GFP (n=13); DS: CAV-SCN1A (n=13). Separate analysis of males and females is shown in Figure 6 . *p<0.05; **p<0.01; ***p<0.001.
[0141] Figure 5 A to Figure 5Figure 2B shows the percentage of male (A) and female (B) DS mice that remained free of heat-induced seizures after hippocampal injection of CAV-GFP or CAV-SCN1A at 5 weeks of age. The dashed line indicates the median seizure onset temperature. DS: CAV-GFP, male n=8, female n=2; DS: CAV-SCN1A, male n=8, female n=6. Figure 5 C to Figure 5 D in Figure 2 shows the survival curves of male (C) and female (D) DS mice injected with CAV-GFP or CAV-SCN1A at P21. DS: CAV-GFP, male n=25, female n=27; DS: CAV-SCN1A, male n=25, female n=20. Figure 5 E to Figure 5 Figures F illustrate the percentage of male (E) and female (F) DS mice that remain free of heat-induced seizures. Dashed lines indicate median seizure onset temperature. DS:CAV-GFP, male n=6, female n=14; DS:CAV-SCN1A, male n=17, female n=15.
[0142] Figure 6 A in Figure 2 depicts the percentage of spontaneous alternation in males and females in the Y-maze following gene therapy in adolescent mice. The test was performed 5-10 days after injection (median age P42, range P39-P43). The dashed line indicates the level of randomness expected for random alternation. The markers above the bars indicate statistical analysis using a one-sample t-test relative to 50%. WT: CAV-GFP, male n=3; female n=6; WT: CAV-SCN1A, male n=6, female n=7; DS: CAV-GFP, male n=6, female n=5; DS: CAV-SCN1A, male n=8; female n=2. In Figure 2 Figure 6 In B, the open field test was performed 9-17 days after injection (median age P50, range P45-P53). Statistical analysis used one-way ANOVA followed by Tukey. WT: CAV-GFP, male n=9, female n=5; WT: CAV-SCN1A, male n=7, female n=6; DS: CAV-GFP, male n=6, female n=7; DS: CAV-SCN1A, male n=9, female n=4. Figure 6C in the figure shows the percentage of spontaneous alternation in males and females in the Y-maze after gene therapy in young mice (P21). The test was performed 8-14 days after injection (median age P36, range P29-P39). The dotted line indicates the random level expected for random alternation. The marks above the bar graph indicate statistical analysis using a single sample t-test relative to 50%. WT: CAV-GFP, male n=9; female n=10; WT: CAV-SCN1A, male n=4, female n=8; DS: CAV-GFP, male n=4, female n=9; DS: CAV-SCN1A, male n=2, female n=8. Figure 6 D in Figure 2 shows the distance moved in the open field after gene therapy in young mice. The test was performed 9-17 days after injection (median age P37, range P30-P41). Statistical analysis used a one-way ANOVA followed by Tukey. WT: CAV-GFP, male n = 8; female n = 9; WT: CAV-SCN1A, male n = 5, female n = 7; DS: CAV-GFP, male n = 3, female n = 8; DS: CAV-SCN1A, male n = 9, female n = 4.
[0143] Hippocampal injection of CAV-SCN1A improves epileptic phenotype in severe stages of DS
[0144] As mentioned above, in SCN1A A1783V / WT In mice, the severity of the epileptic phenotype subsides after the 4th week of life. Therefore, it was determined whether exogenous Nav1.1 activity after CAV-SCN1A injection could prevent recurrent spontaneous epileptic seizures during severe stages of the disease, such as in young DS mice less than 5 weeks of age. To this end, bilateral hippocampal injections were performed at the onset of symptoms at P21-P24. Initially, CAV-SCN1A injections reduced the incidence of premature death by approximately 40% ( 1.2 % in mice injected with CAV-GFP) compared to mice injected with CAV-GFP. Figure 7 Continuous video recordings of a subset of mice from 24h to 36h after injection showed that all DS mice experienced spontaneous convulsive seizures 12h after injection ( Figure 7 B and Figure 8 ). However, at 36 h post-injection, DS mice injected with CAV-SCN1A showed a significant (p<0.5) reduction in the number of convulsive seizures, whereas seizures persisted in those mice treated with CAV-GFP ( Figure 7 B, 36h and Figure 8 ).
[0145] Two weeks after the injection, electrodes were implanted in the hippocampus and neocortex to measure abnormal neuronal activity. CAV-SCN1A treatment was found to reduce the number of epileptic spikes observed in both regions ( Figure 7D to Figure 7 Treatment with CAV-SCN1A injections in DS mice also reduced susceptibility to heat-induced seizures, completely preventing heat-induced seizures in approximately 30% of treated mice ( Figure 7 C) and elevated the seizure threshold temperature in mice that remained susceptible to heat-induced seizures ( Figure 7 In conclusion, in severe stages of DS, CAV-mediated expression of Nav1.1 improves survival, reduces the occurrence of spontaneous seizures and epileptic spikes, and increases the temperature threshold for heat-induced seizures ( Figure 7 ).
[0146] Figure 7 Figure A shows the survival curves of WT and DS littermates injected with CAV-GFP or CAV-SCN1A at P21-P24. WT: CAV-GFP (n=13); WT: CAV-SCN1A (n=17); DS: CAV-GFP (n=42); DS: CAV-SCN1A (n=48). For separate analysis of males and females, see Figure 5 . Figure 7 B shows video monitoring of convulsive seizures 12h and 36h after injection. DS: CAV-GFP (n=5); DS: CAV-SCN1A (n=4). For additional data on individual mice, see Figure 8 . Figure 7 C in Figure 2 shows mice that remained free of heat-induced seizures. The dashed line indicates the median seizure temperature. DS: CAV-GFP (n=20); DS: CAV-SCN1A (n=33). Separate analysis of males and females is shown in Figure 6 . Figure 7 D to Figure 7 Figure 5 shows data from deep electrodes (D, E) or cortical electrodes (F, G) two weeks after treatment. Also depicted are exemplary traces ( Figure 7 D in Figure 7 F in) and quantification of spike frequency ( Figure 7 E in Figure 7 DS: CAV-GFP (n=5 for E, n=16 for G); DS: CAV-SCN1A (n=5 for E, n=19 for G). No epileptic activity was detected in WT mice injected with CAV-GFP or CAV-SCN1A (n=2 for each depth electrode and n=9, n=10 for cortical electrodes, respectively). *p<0.05; **p<0.01; ***p<0.001.
[0147] Figure 8A subset of mice video recorded 14h-36h after injection is shown.
[0148] Figure 8 A depicts the number of seizures per mouse. Figure 4 The mean number of seizures at 36 hours is depicted in B. Figure 8 Panel B shows the change in spontaneous seizure frequency over 36 hours (Chi-square test p=0.013).
[0149] CAV-SCN1A injection corrects background ECoG activity and partially corrects working memory deficits in DS mice
[0150] Spectral analysis of the ECoG signal 2 weeks after injection was performed to further explore the effects of exogenous Nav1.1 activity in WT mice and the potential therapeutic effect of this treatment on background, non-epileptic brain oscillations. In WT mice, injection of CAV-GFP or CAV-SCN1A did not alter the spectral ECoG curve, and the power was also similar to that of untreated mice ( Fig. 9 A to Fig. 9 F in ; data for untreated mice redrawn from (Fadila et al., 2020). This disclosure demonstrates that the CAV-2 vector and exogenous Nav1.1 activity in excitatory and inhibitory neurons do not significantly affect whole-brain oscillations. Mice with DS exhibit overall lower power background ECoG activity compared to WT mice (Fadila et al., 2020). Here, the power of the ECoG signal in DS mice injected with CAV-GFP was also lower than that in WT mice (p ≤ 0.002) and similar to that in untreated DS mice ( Fig. 9 In C, data for untreated mice are redrawn from (Fadila et al., 2020). In contrast, power was higher in DS mice treated with CAV-SCN1A, primarily in the delta and theta bands ( Fig. 9 B to Fig. 9 E). Thus, exogenous Nav1.1 activity generated by CAV-SCN1A injection also corrected background ECoG activity in DS mice.
[0151] We also tested whether exogenous Nav1.1 activity affects the expression of other sodium channels, as it is thought that there may be a physiological balance between sodium channel levels. We found that CAV-SCN1A injection did not alter mRNA levels of any other voltage-gated sodium channel isoforms in control or DS mice ( Fig.10 ).
[0152] Next, we examined the effects of CAV-SCN1A on cognitive performance. We found that CAV-SCN1A injection had no adverse effect on the performance of WT mice, and that DS mice showed a trend toward improved performance in the Y-maze ( Fig. 9F in the figure), and a trend toward decreased hyperactivity in the open field ( Fig.11 In conclusion, CAV-SCN1A treatment has a positive impact on non-epileptic DS features in addition to its effects on epilepsy.
[0153] Fig. 9 A to Fig. 9 Figure B illustrates examples of background ECoG traces and power density curves for WT (A) and DS (B) mice. Fig. 9 C to Fig. 9 Figures in E illustrate total power (C, 0.5 Hz-100 Hz), power in the delta band (D, 0.5 Hz-3.9 Hz), and theta band (E, 4 Hz-8 Hz). Data for untreated mice are re-plotted from (Fadila et al., 2020). Statistical analysis in Figures in C-E used one-way ANOVA (for WT or DS mice, respectively). WT: CAV-GFP (n=9); WT: CAV-SCN1A (n=10); DS: CAV-GFP (n=16); DS: CAV-SCN1A (n=19). Fig. 9 F in the figure illustrates spontaneous alternation in the Y-maze. The dashed line indicates the random level expected for random alternation. The markers above the bars indicate statistical analysis using a one-sample t-test relative to 50%. WT: CAV-GFP (n=19); WT: CAV-SCN1A (n=12); DS: CAV-GFP (n=11); DS: CAV-SCN1A (n=10). Fig. 9 The G in the figure indicates the distance moved in the open field. Statistical analysis was performed using one-way ANOVA: WT: CAV-GFP (n=18); WT: CAV2-SCN1A (n=12); DS: CAV-GFP (n=11); DS: CAV-SCN1A (n=13). Separate analysis of males and females is described in Figure 8 . *p<0.05; **p<0.01; ***p<0.001.
[0154] Fig.10 Relative expression of voltage-gated sodium channels is illustrated. Hippocampi were isolated one month after treatment. For all samples, expression was first normalized to the expression levels of 2 endogenous controls (Gusb and Tfrc) to calculate ΔCt, and then normalized to expression in WT mice treated with CAV2-GFP (to calculate ΔΔCt). WT: CAV-GFP n=13; WT: CAV-SCN1A n=8; DS: CAV-GFP n=9; DS: CAV-SCN1A n=9.
[0155] Total RNA was isolated using the Purelink RNA Micro Kit according to the manufacturer's instructions (Thermo Fisher Scientific, Life Technologies, Carlsbald, CA, USA). cDNA was synthesized from 500 ng RNA using the Maxima H Minus cDNA Synthesis Kit (Thermo Fisher Scientific, Life Technologies, Carlsbald, CA, USA). For quantitative real-time PCR (qPCR), the StepOnePlus The TaqMan Gene Expression Assay (Applied Biosystems, Thermo Fisher Scientific, Life Technologies, Carlsbald, CA, USA) was used on a real-time PCR system (Applied Biosystems, Thermo Fisher Scientific, Life Technologies, Carlsbald, CA, USA) and reactions were performed in triplicate in a final volume of 10 μl with 5 ng of RNA as template. The following assays were used: Sen1a (Mm00450580_m1), Scn2a (Mm01270359_m1), Scn3a (Mm00658167_m1), Scn8a (Mm00488110_m1), Scn1b (Mm00441210_m1), Scn2b (Mm01179204_g1), Scn3b (Mm00463369_m1), as well as Gusb (Mm00446953_m1) and Tfrc (Mm00441941_m1), as endogenous controls. For all assays, 100% efficiency, dynamic range, and lack of genomic DNA amplification were verified. Geometric means of endogenous controls were used and relative to expression in WT mice injected with GFP, with 2 -ΔCT Methods Relative expression was calculated.
[0156] Thalamic delivery of CAV-SCN1A reverses epileptic phenotypes in juvenile DS mice
[0157] In addition to hippocampal dysfunction, thalamic dysfunction has been shown to contribute to network hypersynchrony and epilepsy in DS.
[0158] Therefore, we tested whether thalamic injection of CAV-SCN1A also affects DS epilepsy in young mice. Due to the relatively high input to the thalamus, robust local and widespread transgene expression was found in both WT and DS mice ( Fig.11 Again, CAV-SCN1A reduced the incidence of premature mortality ( Fig.11A in ), and reduced susceptibility to heat-induced seizures ( Fig.11 In addition, cortical ECoG recordings showed that exogenous Nav1.1 activity reduced the frequency of epileptic spikes ( Fig.11 C in Fig.11 D) and corrected for background activity ( Fig.11 E). The present disclosure demonstrates improvements in epileptic phenotypes and whole-brain oscillations following injection of CAV SCN1A into the thalamus or hippocampus of DS mice.
[0159] Fig.11 Panel A shows the survival curves of WT and DS littermates injected with CAV-GFP or CAV-SCN1A. WT: CAV-GFP (n=24); WT: CAV-SCN1A (n=31); DS: CAV-GFP (n=44); DS: CAV-SCN1A (n=25). Fig.11 Figure 5B shows the percentage of mice that remained free of heat-induced seizures. The dashed line indicates the median seizure onset temperature. DS: CAV-GFP (n=28); DS: CAV-SCN1A (n=20). Separate analysis of males and females is shown in Fig.12 . Fig.11 C to Fig.11 D in Figure 2 shows data from two weeks after treatment when cortical electrodes were implanted. An exemplary trace is depicted ( Fig.11 C) and quantification of spike frequency ( Fig.11 D). Fig.11 Panel E illustrates total ECoG power (0.5 Hz-100 Hz). WT: CAV-GFP (n=11); WT: CAV-SCN1A (n=13); DS: CAV-GFP (n=14); DS: CAV-SCN1A (n=10).
[0160] Fig.12 A to Fig.12 Panel B shows the survival percentage curves of male (A) and female (B) DS mice injected with CAV-GFP or CAV-SCN1A at P21. DS: CAV-GFP, male n=16, female n=28; DS: CAV-SCN1A, male n=15, female n=10. Fig.12 C to Fig.12 D in Figure 2 shows the percentage of male (C) and female (D) DS mice that remain free of heat-induced seizures. The dashed line indicates the median seizure onset temperature. DS: CAV-GFP, male n=7, female n=14; DS: CAV-SCN1A, male n=11, female n=9.
[0161] Next, we determined whether injections of CAV-SCN1A into the thalamus and hippocampus could further enhance the therapeutic effects of exogenous Nav1.1 activity. Indeed, following these dual depositions along the needle tracks, DS mice treated with CAV-SCN1A exhibited a greater than 80% change in survival ( Fig.13 A) and significant protection against heat-induced seizures, with only two mice out of 11 tested experiencing heat seizures ( Fig.13 In addition, similar to the effects after hippocampal or thalamic administration, CAV-SCN1A reduced the number of epileptic spikes and increased the power of the background ECoG.
[0162] Thalamic and hippocampal co-injection of CAV-SCN1A protects against heat-induced seizures in juvenile mice
[0163] In conclusion, treatment of juvenile DS mice with CAV-SCN1A injected into the hippocampus or thalamus significantly ameliorated their epileptic phenotype, however, co-delivery provided even greater protection against SUDEP and heat-induced seizures.
[0164] Fig.13 showed that co-injection of CAV-SCN1A into the thalamus and hippocampus into young mice protected against heat-induced seizures. Fig.13 Panel A shows the survival rate of DS mice injected with CAV-GFP or CAV-SCN1A. DS: CAV-GFP (n=28); DS: CAV-SCN1A (n=19). Fig.13 Figure 5B shows the percentage of mice that remained free of heat-induced seizures. The dashed line indicates the median seizure onset temperature. DS: CAV-GFP (n=5); DS: CAV-SCN1A (n=11). Separate analysis of males and females is shown in Fig.14 . Fig.13 C to Fig.13 D in Figure 2 shows data from two weeks after treatment when cortical electrodes were implanted. An exemplary trace is depicted ( Fig.13 C) and quantification of spike frequency ( Fig.13 D). Fig.13 Panel E illustrates total ECoG power (0.5 Hz-100 Hz). WT: CAV-GFP (n=5); WT: CAV-SCN1A (n=4); DS: CAV-GFP (n=6); DS: CAV-SCN1A (n=10).
[0165] Fig.14 A to Fig.14Panel B shows the survival curves of male (A) and female (B) DS mice injected with CAV-GFP or CAV-SCN1A at P21. DS: CAV-GFP, male n=15, female n=14; DS: CAV-SCN1A, male n=9, female n=10. Fig.14 C to Fig.14 D in Figure 2 shows the percentage of male (C) and female (D) DS mice that remain free of heat-induced seizures. The dashed line indicates the median seizure onset temperature. DS:CAV-GFP, male n=4, female n=1; DS:CAV-SCN1A, male n=5, female n=6.
[0166] Fig.15 A in Figure 2 shows that there was no statistical difference in the survival rate of DS mice after CAV-SCN1A was injected into the hippocampus, thalamus, or dual injection into both locations. Figure 7 A in Fig.11 A in Fig.13 The same data presented in A are shown in , and the shaded areas depict 95% confidence intervals. Fig.15 Figure B shows that injection of CAV-SCN1A into both the thalamus and hippocampus provided greater protection against heat-induced seizures. Figure 7 C in Fig.11 B in Fig.13 The same data are presented in B, and the shaded areas depict 95% confidence intervals.
[0167] Hippocampal injection of CAV-NSE-SCN1A in an Alzheimer's disease mouse model resulted in marked behavioral and histopathological changes The level of markers was restored to near wild type
[0168] Fig.16 Figure A illustrates the design of the study, in which two CAV-2 vectors carrying either the mCitrine cassette or a codon-modified SCN1AORF with a fused HA tag were bilaterally injected into the hippocampus of Alzheimer's disease mouse models (5XFAD and J20). 5XFAD mice carry a human amyloid precursor protein (APP) transgene and a presenilin 1 transgene and begin to develop plaques at 2 months of age. J20 mice express human APP695 / 751 / 770, which contains a Swedish double mutation (K670N / M671L) at the β-secretase cleavage site and a V717F mutation at the γ-secretase cleavage site. The transgene is driven by the PDGFβ promoter. J20 mice develop plaque deposits and cognitive deficits at approximately 6 months of age. ITR: inverted terminal repeat. ψ: packaging signal. NSE (promoter): neuron-specific enolase. pA: polyadenylation signal.
[0169] exist Fig.16In medium B, use a stereotaxic instrument to place the carrier (about 1 μl, containing 10 9 Vector particles) were injected into the hippocampus. Exogenous Nav1.1 was detected using immunohistology against the HA tag. The second and third columns are higher magnifications of the black and white boxes in the first column, respectively.
[0170] Fig.16 Figure C shows the physiological effects of CAV-2-mediated exogenous Nav1.1 on working memory in the Y-maze test of 4- and 5-month-old J20 and 5XFAD mice. The Y-maze is a behavioral test that measures the willingness of rodents to explore a new environment. The test is performed in a Y-shaped maze with three arms at 120° angles to each other. The mice are allowed to explore the arms freely. Over the course of multiple entries, the mice should show a tendency to enter the arms that were less recently visited. The Y-maze allows one to quantify cognitive deficits and assess the effects of novel entities on cognition. Many parts of the brain, especially the hippocampus, are involved in this task.
[0171] Fig.16 DE in depicts and shows amyloid burden identified by Thioflavin S analysis (white box) and quantification in the hippocampus and cortex of 9 month old J20 mice injected with two vectors.
[0172] discuss
[0173] DS is an intractable childhood epileptic encephalopathy with a high mortality rate compared to other developmental epilepsies. SUDEP is the leading cause of death, with most occurring before the age of 10 years. Importantly, pharmacological seizure control in DS is notoriously difficult despite the availability of multiple therapies and recent advances in treatment options.
[0174] Therefore, novel treatments are urgently needed. In addition to the life-threatening epilepsy phenotype, individuals with DS suffer from non-epileptic comorbidities, including developmental delays, cognitive impairments, and hyperactivity. While these behavioral deficits significantly impact the quality of life of patients and families, the therapeutic toolbox for addressing this burden is limited.
[0175] According to the present disclosure, CAV-mediated expression of Nav1.1 via codon-modified SCN1AORF significantly improved comorbidities in juvenile and adolescent DS mice, improved epilepsy phenotypes, corrected background ECoG activity, and improved cognitive function. Notably, the present disclosure relates to the only treatment method that is effective during the severe and chronic stages of DS.
[0176] Compared with other DS mouse models, C57BL / 6J-Scn1a A1783V / WTThe mice displayed a severe epileptic phenotype (Han et al., 2020; Niibori et al., 2020), which may make this model particularly resistant to treatment. Specifically, similar to patients with DS, all mice experienced spontaneous epileptic seizures ( Fig.10 ) and heat-induced seizures within the range of clinical febrile seizures. In addition, although the mortality rate in these mice was higher compared with the risk reported in patients ( Figure 7 , Fig.11 , Fig.13 ), but it should be noted that the mice did not receive any anti-seizure medications or emergency care for prolonged seizures. Therefore, the present disclosure relates to a therapeutic approach for a severe epilepsy phenotype that faithfully represents the clinical severity of DS in humans and that can be combined with traditional anti-seizure medications to potentially achieve even greater therapeutic outcomes. Furthermore, effective gene therapy treatment in this model should overcome the persistent membrane expression of the dysfunctional mutant SCN1A allele compared to other models carrying SCN1A truncating mutations. Despite the challenges of this DS model, the present disclosure demonstrates the therapeutic efficacy of CAV-SCN1A and highlights the clinical potential of this therapeutic approach and vector.
[0177] Notably, in contrast to previous efforts to provide gene-specific treatments for DS, which only tested therapeutic effects when administered during the asymptomatic, pre-epileptic, or chronic phases, CAV-SCN1A has a demonstrated effect across multiple disease stages ( Figures 4 to 13 In severe stages of the disease, CAV-SCN1A improved survival, reduced the occurrence of spontaneous seizures, decreased the frequency of epileptic spikes, and protected against heat-induced seizures ( Figure 7 , Fig.11 , Fig.13 In the chronic phase of the disease, improvements in epilepsy are demonstrated by a decrease in the frequency of epileptic spikes and a decrease in sensitivity to heat-induced seizures, as the frequency of spontaneous seizures and the incidence of SUDEP are lower ( Figure 4 ). Furthermore, because this treatment relies on vector-mediated delivery of SCN1AORF rather than transcriptional activation of one functional Nav1.1 copy, it should be applicable to patients with both truncating and missense mutations in SCN1A.
[0178] Complete cure of DS epilepsy is extremely challenging. During the symptom-free period, administration of antisense oligonucleotide treatment at P2 to enhance SCN1A transcription prevented premature mortality, but spontaneous seizures were still observed. Moreover, when the treatment was given at P14, still in the intermediate stage of preeclampsia, complete protection from mortality was not achieved. Similarly, epileptic spikes and spontaneous seizures were still detected after neonatal dCas9-based SCN1A activation, and premature mortality (although survival was improved) was still evident after viral-mediated overexpression of the voltage-gated sodium channel β subunit. Likewise, when treatment was administered during the chronic phase of the disease, abnormal epileptic activity still persisted ( Figure 4 ).
[0179] Notably, CAV-SCN1A injections in the hippocampus or thalamus had similar effects on epilepsy ( Figure 7 , Fig.11 ), implicating these regions in DS pathophysiology. Combined delivery to both regions had similar protective effects against premature death ( Fig.15 A in ), but had a greater protective effect against heat-induced seizures ( Fig.15 B in Figure ). This is likely due to the greater biodistribution of exogenous functional Nav1.1. Interestingly, different circuit-specific neuronal dysfunctions were described for each of these regions. Disinhibition was implicated as the culprit in the hippocampus. In contrast, complex neuronal changes were reported in the thalamus, with reduced activity of inhibitory and excitatory neurons, as well as hyperexcitability of inhibitory thalamic reticular nucleus neurons leading to enhanced cortico-thalamic oscillations and seizures. Thus, unexpected and superior therapeutic effects of CAV-SCN1A were observed despite seemingly opposing local neuronal dysfunction, further highlighting the efficacy and potential of this treatment.
[0180] A major challenge in CNS targeted gene delivery is the need to transduce enough neurons within key brain regions to trigger global changes in network function. The present disclosure further demonstrates the critical role of Nav1.1 expression within the injection site and the broad therapeutic effects of transfection with CAV vectors, as well as their ability to reverse expression, resulting in widespread CNS gene expression. Despite only two injection sites, therapeutic effects can be seen even with only a relatively small number of neurons transduced due to the unique properties of CAV.
[0181] In one aspect, the present disclosure demonstrates a positive overall effect triggered by restoring Nav1.1 expression within a tightly connected neuronal network central to the injection site but including multiple projection neurons (mostly excitatory) from various additional brain regions ( Figure 1 , Figure 2). This corrected Nav1.1 expressing neuron population can now prevent the generalization of epileptic activity, with additional corrective contributions to neuronal networks that are not directly transduced, which explains the ability of the treatment to reverse epilepsy, correct background neuronal activity, and positively affect cognitive abilities. In addition, it can also explain the wide time window for therapeutic intervention, and the ability to reverse symptoms even in adolescent mice. In some aspects, the present disclosure further illustrates that disruption of the activity of individual neurons within the connecting hub can disrupt epileptic network dynamics, suggesting that transduction of all neurons may not be necessary for effective treatment.
[0182] According to certain embodiments, the present disclosure relates to CAV-mediated SCN1A delivery as a treatment method for children and adolescents with DS-associated SCN1A missense mutations and truncating mutations. The present disclosure relates to a vector for reversing DS or its pathology. In certain embodiments, the vector comprises a first nucleic acid sequence encoding a portion of the CAV-2 genome and a second nucleic acid sequence encoding a functional Nav1.1 sodium channel.
[0183] In certain embodiments, the viral vector may further comprise a first regulatory sequence encoding a transcriptional control region. The transcriptional control region may optionally include a promoter and / or enhancer region for transcriptional control. In certain embodiments, the promoter region comprises a promoter sequence encoding at least one promoter selected from the group consisting of CAG, hSyn, NSE and Dlx5 / 6. In certain embodiments, the second nucleic acid sequence is operably linked to a first regulatory sequence for expressing a functional Nav1.1 sodium channel in a mammalian cell. In certain embodiments, the first regulatory sequence is controllable to drive the positive expression of the Nav1.1 sodium channel. The present disclosure relates to a viral vector configured for transcriptional regulation and can drive positive regulation and / or negative regulation of the expression of an exogenous functional Nav1.1 sodium channel.
[0184] According to certain embodiments, the second nucleic acid sequence is an engineered SCN1AORF produced by eliminating at least one short repeat sequence from natural SCN1A. In some embodiments, the second nucleic acid sequence is produced by eliminating at least one short repeat sequence encoding the transmembrane portion of a functional Nav1.1 sodium channel. The present disclosure relates to an engineered CAV-2SCN1A vector, wherein a region of the vector has been engineered, such as by deleting a short repeat sequence, to prevent SCN1A rearrangement when subcloned into a plasmid and propagated.
[0185] The present disclosure also relates to a method for promoting the reversal of DS disease or its symptoms, the method comprising administering a therapeutically effective amount of CAV-2SCN1A viral vector to a mammal. The method results in changes in the balance of neural network activity induced by the vector. Mammals preferably include humans and other species suitable for treatment and / or scientific research, such as mice, rats, pigs, monkeys or other suitable mammals. In certain embodiments, the viral vector is administered to the central nervous system of a mammal. It is also envisioned that the viral vector can be administered to at least one brain region. In some embodiments, at least one brain region can be selected from the group consisting of the hippocampus and the thalamus. However, the present disclosure is not intended to be limiting, and it is envisioned that the vector can be effectively administered to other regions of the brain or CNS and promote positive clinical outcomes. A feature of the present disclosure is that the viral vector can be administered before the development of a chronic form of DS disease or its symptoms, thereby preventing premature death and promoting the reversal of DS and its symptoms.
[0186] The present disclosure relates to a CAV-2SCN1A vector that can be administered to children or adolescents with DS-related missense mutations or truncated mutations in the SCN1A gene. In certain embodiments, after administration of the viral vector, the mammal is monitored for a reduction in epileptic seizures, and if the desired clinical results are not obtained, a second therapeutically effective amount of the vector can be administered. For example, desirable clinical results can be seen by correcting Nav1.1 expression, DS reversal, reduction in epileptic seizures, and improvement of non-epileptic phenotypes of DS (including cognitive deficits and hyperactivity). In one aspect of the present disclosure, the method may include co-administering a therapeutically effective amount of an anti-epileptic seizure drug.
[0187] The present disclosure also relates to compositions for correcting the expression of Nav1.1 and its pathology, such as but not limited to the scope of DS, epilepsy or Alzheimer's disease. In certain embodiments, the composition comprises a viral vector for treating pathological conditions of SCN1A mutation and Nav1.1 sodium channel miscoding, the viral vector comprising a first nucleic acid sequence encoding a CAV-2 vector and a second nucleic acid sequence encoding a functional Nav1.1 sodium channel. In certain embodiments, the viral vector optionally comprises a first regulatory sequence, and the second nucleic acid sequence is operably connected to the first regulatory sequence for controlling the expression of the Nav1.1 sodium channel in mammalian cells. In certain embodiments, the first regulatory sequence optionally comprises a promoter region containing a promoter sequence encoding one of the aforementioned promoters (such as NSE). It is envisioned that other promoters and / or enhancers can be used, for example, promoters and / or enhancers suitable for preferentially expressing SCN1A in neurons.
[0188] In certain embodiments, the present disclosure relates to vectors for compensating for the functional loss of endogenous Nav1.1 and treating pathological conditions associated with SCN1A mutations and Nav1.1 sodium channel miscoding. In some embodiments, the vector comprises a first nucleic acid sequence encoding at least a portion of the CAV-2 genome; a second nucleic acid sequence encoding a functional Nav1.1 sodium channel; a first regulatory sequence encoding a transcription control region, the transcription control region comprising a promoter or enhancer or elongation factor sequence, the promoter or enhancer or elongation factor sequence encoding at least one promoter / enhancer / elongation factor selected from the group consisting of the following items: E2, E6, EF1, CAG, hSyn, Dlx5 / 6 and NSE, and preferably NSE; wherein the second nucleic acid sequence is operably connected to the first regulatory sequence for controlling the transcriptional expression of the SCN1A open reading frame (ORF) in mammalian cells.
[0189] In certain embodiments, the vector can be designed so that the second nucleic acid sequence is an engineered SCN1A ORF; and wherein the engineered SCN1A ORF is generated by eliminating at least one short repeat sequence from a codon-modified SCN1A ORF. In some embodiments, the second nucleic acid sequence is a sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% homology with a nucleic acid sequence selected from the group consisting of Sequence ID No. 12 and Sequence ID No. 14. In other embodiments, the second nucleic acid sequence is a sequence encoding a protein having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% homology with an amino acid sequence selected from the group consisting of Sequence ID No. 15 and Sequence ID No. 16.
[0190] In other embodiments, the vector can be designed such that the second nucleic acid sequence is generated by eliminating at least one short repeat sequence in the ORF encoding the transmembrane portion of a functional Nav1.1 sodium channel.
[0191] In further embodiments, the vector has therapeutic activity in children or adolescent individuals with misexpression of the gene encoding Nav1.1, such as in the case of SCN1A missense mutations or truncating mutations associated with Dravet syndrome, and in other pathological conditions such as epilepsy or Alzheimer's disease.
[0192] In certain embodiments, the vector can be optimized for preferential expression of the SCN1A ORF in neurons and / or configured for transcriptional regulation. In certain embodiments, the SCN1A ORF encodes amino acid SEQ ID NOs 15 and 16, which encode WT and synthetic Nav1.1 proteins lacking the short amino acid sequence VIIDKPATDDN, respectively. These amino acid sequences are normally expressed in the brain, while, for example, SEQ ID NOs 12 and 14 encode genetic sequences for expressing somatic Nav1.1.
[0193] The present disclosure also relates to a method for compensating for the functional loss of Nav1.1 and treating a pathological condition associated with SCN1A mutations and Nav1.1 sodium channel miscoding, the method comprising administering a therapeutically effective amount of a vector to a mammal. In some embodiments, the vector can be administered to the central nervous system of a mammal, or to at least one brain region. In certain embodiments, the vector can be administered to at least one brain region selected from the group consisting of the hippocampus and the thalamus. In other embodiments, the vector can be administered before a chronic form of Dravet syndrome disease or its comorbidity develops. In certain embodiments, the vector can be administered to treat a chronic form of Dravet syndrome disease or its comorbidity.
[0194] In certain embodiments, after the carrier is applied, the method also includes inducing the expression of functional Nav1.1 sodium channel. In other embodiments, the carrier can be applied to the infancy, adolescence, adulthood or old mammals with missense mutation or truncation mutation in SCN1A gene. In certain embodiments, after the carrier is applied, the method also includes monitoring the expected clinical results of mammals, such as the alleviation or improvement of pathological conditions (such as DS, epilepsy, Alzheimer's disease and other Nav1.1 related pathological conditions), and if the expected clinical results are not obtained, the carrier of the second therapeutically effective amount is applied until the therapeutic results are obtained.
[0195] In some embodiments, the vector is deposited at the injection site, and the vector can be delivered to the injection site and to multiple sites containing projection neurons from different brain regions. In some embodiments, the method of treatment further comprises administering a therapeutically effective amount of an anti-seizure, epilepsy, or Alzheimer's disease drug.
[0196] In some embodiments, a therapeutically effective amount of the vector may be administered to treat a pathological condition selected from the group consisting of Dravet syndrome, epilepsy, and Alzheimer's disease. In addition, the method may be beneficial in cases where altering brain neuronal networks reduces disease symptoms (e.g., autism spectrum disorder (ASD)).
[0197] The present disclosure also relates to a composition for compensating for the functional loss of Nav1.1 and treating SCN1A mutations and Nav1.1 sodium channel miscoding, the composition comprising a viral vector comprising a first nucleic acid sequence encoding at least a portion of the CAV-2 genome and a second nucleic acid sequence encoding a functional Nav1.1 sodium channel; wherein the vector optionally comprises a first regulatory sequence, the second nucleic acid sequence is operably linked to the first regulatory sequence for controlling the transcriptional expression of the SCN1A ORF in a mammalian cell; and wherein the first regulatory sequence comprises a transcription control region comprising a promoter / enhancer / elongation factor sequence, the promoter / enhancer / elongation factor sequence encoding at least one promoter / enhancer / elongation factor selected from the group consisting of: E2, E6, EF1, CAG, hSyn, Dlx5 / 6 and NSE, and preferably NSE.
[0198] method
[0199] Vector production
[0200] All CAV-2 vectors used in this study were generated using the seamless ligation cloning extraction (SLiCE) strategy (Zhang et al., 2012). The following promoters were obtained from Addgene: NSE promoter (plasmid #50958 James Bamburg, (Mi et al., 2013)); CAG promoter (plasmid #51274, Pawel Pelczar, (Hermann et al., 2014)); hSyn promoter (plasmid #22909, Edward Callaway, (Nathanson et al., 2009)); Dlx5 / 6 enhancer (plasmid #83900, Gordon Fishell, (Dimidschstein et al., 2016)) Citrine, SCN1A cDNA (Mora-Jimenez et al., 2021) and bovine growth hormone poly A sequence. The fragments were subcloned into the E1 region of E1 / E3 deleted pCAV-2. The vector was then amplified and purified as previously described (Ibanes and Kremer, 2013; Kremer et al., 2000).
[0201] animal
[0202] All animal experiments were approved by the Institutional Care and Use Committees of Tel Aviv University and CNRS. WT and DS mice carrying the global Scn1aA1783V mutation were generated by crossing conditional Scn1aA1783V males (The Jackson Laboratory; stock #0216133) with CMV-Cre females (stock #006054). Mice were housed in the standard animal facility of the Glodschleger Eye Institute at a constant temperature of 22°C with a 12-h light / dark cycle and with ad libitum access to food and water.
[0203] IH
[0204] It is worth repeating that CAV-2-mediated gene transfer is associated with CAR expression patterns on neurons (Soudais et al., 2000; Zussy et al., 2016). As CAR levels change during development and in inflammatory diseases such as Alzheimer's disease, the efficacy of CAV-2 vectors in adolescent and young healthy mice or DS mice may be different. Therefore, CAV-GFP was injected into young healthy mice and DS mice, and transgenic expression was examined. In DS mice, similar strong transgenic expression was found at the injection site and in afferent areas (hippocampus, neocortex, striatum, internal capsule, and thalamus).
[0205] Virus injection
[0206] WT and DS mice aged P21-24 or P35-P36 were randomly assigned to be treated with CAV-2-NSE-GFP (CAV-GFP) or CAV-2-NSE-SCN1A (CAV-2-SCN1A). Mice were anesthetized with ketamine / xylazine (191 mg / kg / 4.25 mg / kg) and carprofen (5 mg / kg) was used for analgesia. Mice were placed in a stereotaxic apparatus (Ultra Precise Stereotaxic Instruments, Stoelting, Wood Dale, IL, USA). A midline incision was made above the skull and a 25G needle was used to punch holes at the injection site. For hippocampal injections, we used the following coordinates: for P21-24, anterior / posterior (AP): -1.8; medial / lateral (ML): ±1.7; dorsal / ventral (DV): -3; for P35-36, AP: -1.7; ML: ±1.8; DV: -3. For thalamic injections at P21-P24, we used the following coordinates: AP: -1.4; ML: ±2.2 DV: -3.5. 1 μl of 1 × 10 ^9 vp; for bithalamo-hippocampal injections, the injection needle was lowered to: ML: ±1.8; PL: ±1.8; DV: -3.5 and 0.5 μl was injected, and after a few minutes, the injection needle was raised to DV: 3 and 0.5 μl was injected. For P21 mice with a distance between bregma and lambdoid suture tip less than 3 mm, the AP coordinates were slightly modified and reduced to AP: -1.7.
[0207] DV coordination was measured from the tip of a bevel injection needle at a rate of 100 nL / min (Quintessential stereotaxic injector, Stoelting, Wood Dale, IL, USA). After injection, the syringe was kept in place for at least 5 minutes to prevent backflow and then slowly retracted. The skin was then closed with sutures and the mice were isolated for 7 days according to TAU BSL-2 safety instructions.
[0208] ECoG and depth electrodes and recordings
[0209] One week after viral injection, cortical or deep electrodes were implanted as previously described (Fadila et al., 2020). Briefly, a midline incision was made above the skull, and fine silver wire electrodes were implanted (130 mm diameter bare electrode; 180 mm diameter coated electrode). We used the previously created injection holes for ECoG or deep electrodes for hippocampal depth recordings, lowering the wire electrodes using the same stereotaxic coordinates used for injection. A reference electrode was placed on the cerebellum; and a ground electrode was subsequently placed behind the neck. The electrodes were connected to a milmax connector, secured with dental cement, and the skin was closed with sutures. Mice were given at least two days to recover before recording.
[0210] During the light period, a video-depth / EcoG recording lasting 2 hours to 4 hours was obtained from a freely moving mouse connected to a T8 Headstage (Triangle BioSystems, Durham, NC, USA) using PowerLab 8 / 35 acquisition hardware and LabChart 8 software (ADInstrumnts, Sydney, Australia). The electrical signal was recorded and digitized at a sampling rate of 1 KHz with a 50 Hz notch filter. LAbChart8 (ADInstrumnts, Sydney, Australia) was used for analysis. The ECoG signal was processed offline with a 0.5 Hz-100 Hz bandpass filter. The power spectral density was calculated using a fast Fourier transform, and the Hann (cosine bell) data window was set to 50% overlap. For each mouse, five to eight 30 s long segments of motionlessness and no epilepsy were taken, but the average of the awake segments of the movement determined by the video recording was followed.
[0211] Heat-induced seizures
[0212] Heat induction was performed one month after injection as described previously (Almog et al., 2021). Briefly, mice were given 10 min to acclimate to the thermal probe and recording chamber. Baseline body temperature was measured and subsequently increased by 0.5°C every 2 min until 40.5°C or until seizures occurred.
[0213] Behavioral experiments
[0214] Behavioral experiments were performed as described previously (Fadila et al., 2020). Spontaneous alternation in the Y maze was performed 5-14 days after injection, and the open field test was performed 9-17 days. Briefly, for the Y maze spontaneous alternation test, mice were placed in a symmetrical Y maze consisting of three opaque white Plexiglas arms (each 35cm L×7.6cm W×20cm H) and allowed to explore freely for 10min. For the open field test, mice were placed in the center of a square (50×50cm) Plexiglas device and their activity was recorded for 10min. Real-time tracking was achieved via a monochrome camera (Basler acA1300-60gm, Basler AG, Ahren, Germany) connected to EthoVision XT 13 software (Noldus Technology, Wageningen, Netherlands).
[0215] Sequence Listing
[0216]
[0217]
[0218] definition
[0219] As used herein, the singular forms "a," "an," and "the" include plural references unless otherwise indicated. For example, "a" component in a composition includes one or more components.
[0220] "Polynucleotide" or "nucleic acid" as used interchangeably herein refers to a polymer of nucleotides of any length, and includes DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase. Polynucleotides may include modified nucleotides, such as methylated nucleotides and their analogs. If present, the nucleotide structure may be modified before or after polymer assembly. The sequence of nucleotides may be interspersed with non-nucleotide components. Polynucleotides may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications include, for example, "caps", substitution of one or more naturally occurring nucleotides with an analog, internucleotide modifications, for example, those with uncharged bonds (e.g., methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.) and those with charged bonds (e.g., phosphorothioates, phosphorodithioates, etc.), those containing side chain moieties, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those containing intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidized metals, etc.), those containing alkylating agents, those with modified bonds (e.g., alpha anomeric nucleic acids, etc.), and unmodified forms of polynucleotides. In addition, any hydroxyl groups typically present in sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional bonds with additional nucleotides, or may be conjugated to a solid support. 5' and 3' terminal OH can be phosphorylated or partially replaced by amine or organic end-capping groups of 1 to 20 carbon atoms. Other hydroxyls can also be derived as standard protecting groups. Polynucleotides can also contain similar forms of ribose or deoxyribose commonly known in the art, including for example 2'-O-methyl-2'-O-allyl, 2'-fluoro-ribose or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars such as arabinose, xylose or lyxose, pyranose, furanose, sedoheptulose, acyclic analogs and abasic nucleoside analogs such as methyl nucleosides. One or more phosphodiester bonds can be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments in which the phosphate is replaced by P(O)S ("thioester"), P(S)S ("dithioester"), "(O)NR2 ("amidate"), P(O)R, P(O)OR', CO or CH2 ("methylal"), wherein each R or R' is independently H or a substituted or unsubstituted alkyl (1-20 C), aryl, alkenyl, cycloalkyl, cycloalkenyl or aralkyl group optionally containing an ether (-O-) linkage. Not all bonds in a polynucleotide need be identical. The foregoing description applies to all polynucleotides referred to herein, including RNA and DNA.
[0221] "Treatment" can be assessed using any endpoint that indicates benefit to the patient, including, but not limited to, (1) inhibition of disease progression to some extent, including slowing and complete cessation; (2) reduction in the number of disease attacks and / or symptoms; (3) reduction in comorbid attacks and / or symptoms; (4) inhibition of disease and / or comorbid symptom progression (i.e., alleviation, slowing, or complete cessation); (5) inhibition of comorbid symptom progression (i.e., alleviation, slowing, or complete cessation); (6) alleviation to some extent of one or more symptoms associated with the condition or its comorbidities; (7) increase in the length of time after treatment without disease manifestation; (8) reduction in mortality at a given time point after treatment; and / or (9) absence of adverse effects after treatment. Treatment can also be assessed using any endpoint that indicates side effects and / or toxicity to the patient.
[0222] "Treating / treatment" or "relieve" refers to therapeutic treatment, wherein the purpose is to slow down (relieve) (if not cure) the target pathological condition or disorder, or to prevent the recurrence of the condition. If after receiving a therapeutic amount of a therapeutic agent, the subject shows a reduction or absence of one or more signs and symptoms of a specific disease or its comorbidities that can be observed and / or measured, then the subject is successfully "treated". The patient may also feel a reduction in the signs or symptoms of the disease or comorbidity. Treatment can achieve a complete response, defined as the disappearance of all signs of the pathological condition, or a partial response, wherein the symptoms or presence of the pathological condition are reduced, preferably by more than 50%, more preferably by 75%. If the patient experiences stable disease, the patient is also considered to be treated. In some embodiments, treatment with a therapeutic agent is effective in rendering the patient disease-free for 3 months, preferably 6 months, more preferably one year, and even more preferably 2 years or more after treatment. These parameters for evaluating successful treatment and improvement of the disease can be easily measured by conventional methods familiar to physicians with appropriate skills in the art.
[0223] It should be understood that aspects and embodiments of the present invention described herein include "comprising," "consisting of," and / or "consisting essentially of" aspects and embodiments.
Claims
1. A vector for providing exogenous Nav1.1 sodium channel, comprising: a first nucleic acid sequence encoding at least a portion of a CAV-2 genome; a second nucleic acid sequence encoding a functional Nav1.1 sodium channel; a first regulatory sequence encoding a transcriptional control region comprising a promoter / enhancer / elongation factor sequence encoding at least one promoter / enhancer / elongation factor selected from the group consisting of an endogenous SCN1A promoter, an endogenous SCN1A enhancer, an endogenous SCN1A transcription factor, E2, E6, EF1, CAG, hSyn, Dlx5 / 6, and NSE, and preferably NSE; The second nucleic acid sequence is operably linked to the first regulatory sequence to control the transcriptional expression of the SCN1A open reading frame (ORF) in mammalian cells.
2. The vector according to claim 1, wherein the second nucleic acid sequence is sequence ID No.
12.
3. The vector according to claim 1, wherein the second nucleic acid sequence is sequence ID No.
14.
4. The vector of claim 1, wherein the second nucleic acid sequence encodes Sequence ID No.
15.
5. The vector of claim 1, wherein the second nucleic acid sequence encodes Sequence ID No.
16.
6. The vector according to claim 1, wherein: The second nucleic acid sequence is an engineered SCN1AORF; and The engineered SCN1A ORF is generated by eliminating at least one short repeat sequence from the codon-modified SCN1A ORF.
7. The vector according to claim 1, wherein the second nucleic acid sequence is generated by eliminating at least one short repeat sequence in the ORF encoding the transmembrane portion of the functional Nav1.1 sodium channel.
8. The vector of claim 1, wherein the vector is designed for use in the treatment of pathological conditions associated with SCN1A mutations or network dysfunction.
9. The vector of claim 1, wherein the promoter / enhancer / elongation factor is NSE.
10. The vector according to any one of claims 1 to 9, wherein the vector has therapeutic activity in individuals with a SCN1A missense mutation or a SCN1A truncating mutation.
11. The vector according to any one of claims 1 to 9, wherein the vector is optimized for preferential expression of SCN1AORF in neurons.
12. The vector according to any one of claims 1 to 9, wherein the vector is therapeutically active in individuals suffering from Dravet syndrome.
13. The vector of any one of claims 1 to 9, wherein the vector has therapeutic activity in an individual suffering from epilepsy.
14. The vector according to any one of claims 1 to 9, wherein the vector has therapeutic activity in an individual suffering from Alzheimer's disease.
15. The vector according to any one of claims 1 to 9, wherein the vector has therapeutic activity in individuals with functional loss of endogenous Nav1.1 activity.
16. The vector of any one of claims 1 to 9, wherein the vector has therapeutic activity in an individual suffering from an autism spectrum disorder.
17. The vector of any one of claims 1 to 9, wherein the vector has therapeutic activity in an individual suffering from a neuronal dysfunction.
18. A method for providing exogenous Nav1.1 channels, comprising: A therapeutically effective amount of the vector according to any one of claims 1 to 9 is administered to a mammal.
19. The method of claim 18, wherein the vector is administered into the central nervous system of the mammal.
20. The method of claim 18, wherein the vector is administered to at least one region of the brain.
21. The method of claim 18, wherein the vector is administered to at least one brain region selected from the group consisting of hippocampus and thalamus.
22. The method of claim 18, wherein the vector is administered prior to the development of a Dravet syndrome phenotype or a comorbidity thereof.
23. The method of claim 18, wherein the vector is administered after the development of the Dravet syndrome phenotype or a comorbidity thereof.
24. The method of claim 18, wherein the vector is administered to treat Dravet syndrome or a comorbidity thereof.
25. The method of claim 18, wherein the vector is administered to prevent the development of Dravet syndrome or a comorbidity thereof.
26. The method of claim 18, wherein after administering the vector, the method further comprises: Inducing the expression of the functional Nav1.1 sodium channel.
27. The method of claim 18, wherein the vector is administered to an individual having a missense mutation or a nonsense mutation in SCN1A.
28. The method of claim 18, wherein the vector is administered to an individual having a truncating mutation in SCN1A.
29. The method of claim 18, wherein the vector is administered to an individual having a mutation affecting splicing of the SCN1A transcript.
30. The method of claim 18, wherein the vector is administered to an individual having a frameshift mutation involving SCN1A.
31. The method of claim 18, wherein the vector is administered to an individual having a mutation in the promoter / enhancer / regulatory region of SCN1A.
32. The method of claim 18, wherein after administering the vector, the method further comprises: monitoring said mammal for a desired clinical outcome, and if said desired clinical outcome is not achieved; A second therapeutically effective amount of the vector according to any one of claims 1 to 9 is then administered.
33. The method of claim 18, wherein the vector is administered to the patient's brain via injection.
34. The method of claim 18, further comprising: A therapeutically effective amount of a seizure medication is administered.
35. The method of claim 18, further comprising: A therapeutically effective amount of an Alzheimer's disease drug is administered.
36. The method of claim 18, further comprising: A therapeutically effective amount of an epilepsy drug is administered.
37. The method of claim 18, wherein: Administration of a therapeutically effective amount of a vector according to any one of claims 1 to 9 to treat Dravet syndrome.
38. The method of claim 18, wherein: A therapeutically effective amount of a vector according to any one of claims 1 to 9 is administered to treat epilepsy.
39. The method of claim 18, wherein: A therapeutically effective amount of the vector according to any one of claims 1 to 9 is administered to treat Alzheimer's disease.
40. The method of claim 18, wherein: Administration of a therapeutically effective amount of a vector according to any one of claims 1 to 9 to treat autism spectrum disorders.
41. The method of claim 18, wherein: A therapeutically effective amount of the vector according to any one of claims 1 to 9 is administered to treat a neurodevelopmental disorder.
42. A composition for providing an exogenous Nav1.1 channel, the composition comprising: The vector according to any one of claims 1 to 9.
